Thomas Powles, MBBS, MRCP, MD shares the groundbreaking results of the NIAGARA study, a global phase 3 trial involving 1,000 patients with muscle-invasive bladder cancer. Dr. Powles breaks down the trial’s design, including the addition of perioperative durvalumab to the standard chemotherapy and cystectomy regimen. The study revealed significant improvements in both event-free survival and overall survival, marking the first time immune therapy has shown a survival advantage in this patient population.
Advertisement
Latest News
Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy.
AUC3 will drive consensus on clinical guidelines that are vague about advanced kidney and bladder cancer treatments.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
In the third part of this series, disparities and the optimization of care is discussed, along with the use of ADT and ARPIs.
In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients.
In the first part of this series, the panel discusses treatments in the post-salvage setting and review therapeutic options.
The COBRA study on SAR-bisPSMA for prostate cancer detection will be presented at the EANM 2024 Congress.
Watch the "Front-Line Therapy in Papillary Renal Cancer" session from Uromigos Live 2024.
View the live recording of the "The Uromigos' Definition of Oligometastatic" session from Uromigos Live 2024.
At ESMO Congress 2024, Drs. Petros Grivas, Bernadett Szabados, and Karine Tawagi discuss ctDNA biomarkers.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, PhDEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center
The Uromigos Live and Unplugged 2024
The Uromigos Live & Unplugged 2024 will take place September 27-29 in Nashville, Tennessee.
This meeting is the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
Expert Interviews
Dr. Brad McGregor shares exciting developments in the MIBC space and the challenges facing the field of GU oncology.
Dr. Kane shares insights into his career trajectory, highlighting moments that led him to specialize and leading in urology.
Dr. Li rationalizes the design and potential impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Conference Coverage
Live meeting highlights
AUC3 will drive consensus on clinical guidelines that are vague about advanced kidney and bladder cancer treatments.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
Video Insights
Clinical discussions with experts in the field
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.